State of Legal Contests Over mRNA and Other Vaccine Mandates (as of January 2026)
This article provides a comprehensive, plain‑language yet legally rigorous account of the current state of legal contests surrounding mRNA COVID‑19 vaccine mandates in the United States as of January 2026. It focuses primarily on students and healthcare workers, the two groups most frequently subjected to compulsory vaccination as a condition of education, employment, or professional licensure.
The analysis integrates federal statutes, Supreme Court docket activity, lower‑court doctrine, and post‑mandate remedial litigation. It distinguishes between what the law clearly says, what courts have actually decided, and what courts have systematically avoided deciding. The focus is strictly legal—not political—and treats mRNA products deployed under Emergency Use Authorization (EUA) as a distinct statutory category with specific consequences for consent, coercion, and accommodation.
This article explains why the central legal questions raised by mRNA mandates remain unresolved, how lower courts narrowed individual‑rights protections during the emergency period, and why 2026 may mark a turning point.
Key Takeaway
mRNA COVID‑19 shots were widely used under Emergency Use Authorization, a legal status that is explicitly different from full FDA approval.
Federal law requires that recipients of an EUA product be told they have the option to accept or refuse it.
Many courts treated refusal as permissible only if the individual accepted severe penalties, such as job loss or expulsion.
In many private-employer and institution-policy challenges, courts avoided deciding whether EUA consent provisions conflicted with mandate enforcement by treating the dispute as a conventional employment or enrollment condition case—even while other mandate categories (OSHA/CMS/federal employee) were litigated on federal statutory authority.
Religious‑freedom protections were narrowed in practice until the Supreme Court corrected the standard in 2023.
Even after that correction, lower courts have often resisted full enforcement of strengthened rights.
Human‑research consent protections were repeatedly raised—and repeatedly set aside.
Although mandates have largely ended, lawsuits over firings, expulsions, and lost income continue.
Lower courts reached inconsistent outcomes under similar facts, signaling the need for Supreme Court clarification.
The Supreme Court is now signaling concern, suggesting unresolved tensions may finally be addressed.
I. Statutory Baseline: What Is Not in Dispute
A. Emergency Use Authorization Is Not Full Approval
Under federal law, mRNA COVID‑19 products administered during the height of the pandemic were distributed pursuant to 21 U.S.C. § 360bbb‑3, the Emergency Use Authorization statute. Congress created the EUA pathway for true emergencies—situations where products must be deployed before the usual approval process is complete.
An EUA product is, by definition, unapproved. This does not mean it is ineffective or unlawful, but it does mean that long‑term safety and efficacy data are incomplete, and that Congress imposed additional safeguards for recipients. These safeguards are not optional; they are statutory conditions of use.
B. The PREP Act Overlay
The Public Readiness and Emergency Preparedness Act (42 U.S.C. § 247d‑6d) provides broad immunity from tort liability for manufacturers and administrators of covered countermeasures. Courts have generally treated the PREP Act as a liability shield, not as a general authorization to override employment law, civil‑rights law, or consent requirements.
C. Religious Accommodation After Groff v. DeJoy
Title VII of the Civil Rights Act requires employers to accommodate sincere religious beliefs unless doing so would impose an undue hardship. For decades, courts interpreted undue hardship loosely, allowing employers to deny accommodations for minimal inconvenience.
In 2023, the Supreme Court corrected this in Groff v. DeJoy, holding that employers must now demonstrate a substantial burden to deny religious accommodation. This change materially altered the legal landscape for healthcare‑worker mandate cases.
II. The Central Fault Line: EUA Use, Consent, and Coercion
A. The “Option to Refuse”
The EUA statute requires that recipients be informed of “the option to accept or refuse” the product. In ordinary language, an option implies a real choice.
Plaintiffs across the country argued that conditioning employment, education, or licensure on receipt of an EUA product rendered that option meaningless. Courts, however, generally reinterpreted this requirement as purely informational, allowing institutions to say, in effect:
You may refuse—but that is being interpreted as “but as result we may still fire you, expel you, or revoke your license”.
This is an odd interpretation of a forbidden mandate.
This interpretation strips the statutory language of practical effect and conflicts with the traditional understanding of informed consent as freedom from coercion or penalty.
B. Reframing as Employment Conditions
Rather than squarely addressing whether EUA mandates conflicted with federal law, courts frequently reframed these cases as routine workplace disputes. By labeling mandates as “conditions of employment,” courts sidestepped the EUA statute entirely and allowed institutions to accomplish indirectly what the statute appears to forbid directly.
III. Human‑Research Protections and Judicial Deference
Federal law governing human‑subjects research—including 42 U.S.C. § 289 and the Common Rule (45 C.F.R. § 46)—requires voluntary participation, informed consent, and freedom from coercion.
Plaintiffs argued that mass administration of unapproved biologics, coupled with ongoing safety data collection, are de facto large‑scale human experimentation. Courts declined to engage this argument, accepting agency characterizations that EUA deployment constituted “public health practice,” even when institutions were contractually bound by federal research‑ethics rules.
This deference elevated administrative labeling over substantive protections.
IV. Students and School‑Attendance Mandates
A. New York and the Supreme Court GVR
In Miller v. McDonald (No. 25‑133), the Supreme Court granted, vacated, and remanded a Second Circuit decision upholding New York’s elimination of religious exemptions for school vaccination. The Court directed reconsideration in light of Mahmoud v. Taylor (2025), signaling renewed scrutiny of regimes that preserve medical exemptions while denying religious ones.
B. West Virginia’s Ongoing Conflict
A West Virginia trial court ruled that the state’s Equal Protection for Religion Act required religious exemptions to school mandates. The state supreme court stayed that decision pending appeal, leaving families in legal limbo.
C. University Liability and Settlements
Universities faced similar exposure. In December 2025, the University of Colorado Anschutz Medical Campus agreed to a $10 million settlement resolving claims that religious exemptions were improperly denied to students and staff. Even where mandates ended, liability remained.
V. Healthcare Workers and Federal Litigation Fronts
A. Does v. Hochul and Supreme Court Review
In Does 1–2 v. Hochul (No. 24‑1015), healthcare workers challenge New York’s categorical denial of religious exemptions. The Supreme Court has requested the views of the Solicitor General—a rare step indicating serious concern.
B. Pleading Standards and Ongoing Resistance
Lower courts, including the Ninth Circuit in Detwiler v. Mid‑Columbia Medical Center, have dismissed cases on technical grounds, requiring plaintiffs to plead religious belief with exceptional specificity while avoiding application of the strengthened Groff standard to EUA‑era decisions.
C. Post‑Mandate Remedies
Even after mandates ended, courts have ordered reinstatement and back pay where exemption processes were arbitrary or discriminatory, recognizing that procedural rights do not expire with policies.
VI. PREP Act, Preemption, and Due Process
Plaintiffs have argued that mandates nullifying the EUA “option to refuse” create a direct conflict with federal law. Courts have narrowly construed preemption and generally avoided ruling on this conflict.
Procedural due‑process claims—focused on lack of notice, standards, or appeals—have seen more success, underscoring courts’ preference for narrow resolutions.
VII. Judicial Avoidance and Institutional Priorities
Across cases, courts resolved disputes through threshold doctrines—standing, pleading defects, and deference—rather than merits rulings. The pattern reflects an implicit prioritization of institutional policy and administrative efficiency over individual rights.
This ordering is in tension with the foundational premise of U.S. law: emergencies test the resilience of rights; they do not erase them.
VIII. Why These Legal Areas Are Likely to Move in 2026
Second Circuit reconsideration in Miller v. McDonald
Movement in Miller v. McDonald is not speculative; it has already been compelled by the United States Supreme Court. In late 2025, the Court vacated the Second Circuit’s prior judgment and remanded the case for reconsideration in light of newly decided Free Exercise precedent. A grant–vacate–remand order is not a procedural courtesy—it nullifies the lower court’s prior ruling and requires a fresh legal analysis under updated constitutional standards.
On remand, the Second Circuit must now reassess whether New York’s school-vaccination regime—which eliminates religious exemptions while preserving medical exemptions—can survive scrutiny under the Free Exercise Clause as clarified by recent Supreme Court decisions. The court cannot simply reaffirm its earlier conclusion; it must explain how that conclusion fits within the Supreme Court’s intervening jurisprudence. Whatever the outcome, the reconsidered decision is highly likely to generate further appellate review, making this one of the most active fault lines in school-mandate litigation.
Supreme Court certiorari decision in Does v. Hochul
The Supreme Court’s handling of Does 1–2 v. Hochul strongly signals that the case is under serious consideration. The Court has taken the unusual step of requesting the views of the Solicitor General, a procedural move known as a CVSG. This step is not routine. It is typically reserved for cases that raise questions of national importance or unresolved conflicts in federal law.
At issue in Does is whether a state may categorically deny religious accommodations to healthcare workers and treat compliance with state law as automatic “undue hardship” under federal civil-rights law. The case also raises potential Supremacy Clause conflicts, because Title VII is a federal statute designed to protect religious exercise in the workplace. A decision to grant or deny certiorari will itself be consequential, but a grant would likely produce the first Supreme Court ruling squarely addressing religious accommodation in the context of emergency-era vaccine mandates.
Expansion of post-mandate damages and reinstatement awards
Although most vaccine mandates have ended, litigation has not. Courts are increasingly confronted with claims seeking back pay, reinstatement, lost benefits, and other damages arising from mandate-era terminations and exclusions. These cases do not depend on whether mandates remain in force; they turn on whether the processes used during the mandate period complied with federal and state law.
What is changing is judicial willingness to treat these cases as moot simply because the underlying policy expired. Instead, courts are recognizing that wrongful termination, denial of accommodation, or exclusion from employment or education can produce ongoing legal injury. As more cases survive early dismissal, institutions face greater exposure to discovery, settlement pressure, and judicially ordered remedies. This remedial expansion is already underway and is likely to accelerate as appellate courts clarify that mandate sunset does not erase liability.
Clarification of how Groff v. DeJoy applies to emergency-era policies
The Supreme Court’s decision in Groff v. DeJoy fundamentally altered the legal standard governing religious accommodation in the workplace. Employers must now show that denying an accommodation would impose a substantial burden, not merely a trivial or speculative inconvenience. This change directly affects a large number of COVID-era mandate cases, many of which relied on minimal operational justifications to deny exemptions.
Lower courts are still working out how Groff applies to emergency-era policies, and the results have been uneven. Some courts have continued to apply pre-Groff reasoning, while others have demanded more rigorous, individualized assessments. This doctrinal instability virtually guarantees further appellate clarification. Whether through circuit-court decisions or Supreme Court review, courts will need to articulate how strengthened religious-accommodation protections operate when employers invoke emergency conditions or public-health rationales.
Why this matters
Taken together, these four developments reflect a legal system that deferred hard questions during an emergency but can no longer avoid them. Supreme Court remands, active certiorari consideration, expanding remedial litigation, and revised civil-rights standards all point toward substantive movement in 2026. The question is no longer whether these issues will be revisited, but how decisively courts will resolve the conflicts left open during the pandemic years.
Conclusion
Congress enacted emergency laws to permit rapid medical response while preserving individual protections. During the COVID‑19 emergency, lower courts often treated those protections as technicalities rather than binding limits.
No Supreme Court decision has yet resolved whether forcing unapproved, emergency‑authorized products as conditions of work or education complies with federal law. That question remains open. With growing financial liability, strengthened civil‑rights standards, and clear signals from the Supreme Court, 2026 may be the year those unresolved conflicts finally receive definitive answers.
Congress, itself, was not mandated to take the experimental genetic injection.
Thank you. This is very good information.
…
Too bad no one seems to be asking two questions that seem fundamental: 1) What is the explicit Constitutional authority allowing Congress to legislate the provisions of 1986 and PREP? 2) If Article III, Section 2 does not explicitly authorize the Supreme Court or its inferior courts (including, presumably, tribunals) to adjudicate disputes between two private parties, then whose justice system, federal or state, is prohibited by 1986 from hearing a controversy in common law between private parties?